Trials / Completed
CompletedNCT03004248
Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines
An Open-Label, Multi-Center Trial to Assess the Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines (SAKURA OPEN-LABEL SAFETY)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,691 (actual)
- Sponsor
- Revance Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a long term safety study of DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines following single and repeat administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Botulinum Toxins, Type A | Intramuscular Injection |
Timeline
- Start date
- 2016-12-09
- Primary completion
- 2018-10-17
- Completion
- 2018-10-17
- First posted
- 2016-12-28
- Last updated
- 2022-07-13
- Results posted
- 2022-07-13
Locations
61 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT03004248. Inclusion in this directory is not an endorsement.